MAKARY NASSER
Biochemical Engineer and environmental sustainability researcher with 4+ years of experience in applied research, environmental remediation and decarbonization technologies, data analysis, regulatory compliance review, and technical program delivery. Proven ability to manage partner deliverables, verify technical data, write clear reports and correspondence, and present complex results to internal, regulatory, and external stakeholders.
Dr. Richard Jayaraj
Neuroscientist with over 15 years of international research experience across four countries, specializing in multi-disciplinary pre-clinical and clinical projects spanning in silico, in vitro, and in vivo disease models and human biomarkers. I started my research journey from a humble background, without access to sophisticated labs or resources, yet went on to complete my PhD […]
Jenna Montgomery Harvey, PhD
I am a neuroscience drug discovery scientist with more than 15 years of experience spanning neurophysiology, neurodegenerative disease research, translational biology, and therapeutic development. Throughout my career, I have worked across academia, biotechnology, and pharmaceutical research, advancing programmes from target identification and validation through candidate nomination and early preclinical development. In recent years, I have […]
Gwang Jin (Josephus) Kim
Senior Data Scientist computational biologist PhD Molecular Medicine with long-term experience delivering end-to-end analytics across disease research and Pharma Biotech environments from multi-omics single-cell bulk RNA-seq ChIP/ATAC to applied ML CNNs sequence models and robust reproducible pipelines. Clinical-facing background from a university hospital setting Freiburg Germany worked with patient-derived cohort data under ethics approval informed […]
Jeffrey M. Skredenske
Accomplished expert in biologics (upstream and downstream) and bioconjugation with deep experience in process development, manufacturing, and process validation. Demonstrated success leading cross-functional teams and managing strategic CDMO partnerships to advance monoclonal antibody and antibody-drug conjugate programs through early- and late-phase clinical trials and IND and BLA preparation and submission. Strong background in high-impact project […]